Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
INIM Pharma
Mölndal, Sweden
- Ownership
- Private
- Development stage
- Other
01
Overview
INIM Pharma developed a local treatment for severe interstitial lung diseases, including idiopathic pulmonary fibrosis (IPF), based on the IMiD class of immunomodulatory compounds. The focus was on optimizing formulation for local lung delivery to reduce systemic side effects. The company was preparing for Phase 1 clinical trials at acquisition and aimed to initiate a Phase 2 study in severe lung disease thereafter.
- Therapeutic areas
- Pulmonology
- Modalities
- Small moleculeImmunomodulatory imide drug
- Industry
- Biotech
02
Partnerships
Nanologica AB
Beyond the preview
Go deeper on INIM Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INIM Pharma.